Dublin, March 18, 2022 (GLOBE NEWSWIRE) -- The "Common Warts - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
This "Common Warts- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Common Warts, historical and forecasted epidemiology as well as the Common Warts market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Common Warts Epidemiology
The Common Warts epidemiology division provide insights about historical and current Common Warts patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Common Warts epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Common Warts Epidemiology
The epidemiology segment also provides the Common Warts epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Common Warts Drug Chapters
Drug chapter segment of the Common Warts report encloses the detailed analysis of Common Warts marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Common Warts clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs
The report provides the details of the marketed product available for Common Warts treatment.
Common Warts Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Common Warts treatment.
Common Warts Market Outlook
The Common Warts market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Common Warts market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Common Warts market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Common Warts Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Common Warts market or expected to get launched in the market during the study period 2019-2032. The analysis covers Common Warts market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Common Warts Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Common Warts key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Common Warts emerging therapies.
Key Topics Covered:
1 Key Insights
2 Report Introduction
3 Common Warts Market Overview at a Glance
3.1 Market Share (%) Distribution of Common Warts in 2019
3.2 Market Share (%) Distribution of Common Warts in 2032
4 Executive Summary of Common Warts
5 Disease Background and Overview
5.1 Introduction
5.2 Signs and Symptoms
5.3 Etiology
5.4 Classification
5.5 Risk Factors
5.6 Histopathology
5.7 Pathophysiology
5.8 Diagnosis
5.9 Differential diagnosis of verruca vulgaris pathology
6 Management and Treatment
6.1 Diagnostic and Treatment Guidelines
6.1.1 British Association of Dermatologists' guidelines for the management of cutaneous warts 2014
7 Epidemiology and Patient Population
7.1 Key Findings
7.2 7MM Total Prevalent Patient Population of Common Warts
7.3 Assumptions and Rationales
7.4 The United States
7.4.1 Diagnosed prevalent cases of Common warts in the United States
7.4.2 Gender specific Prevalence of Common Warts in the United States
7.5 EU-5
7.5.1 Diagnosed Prevalent Cases of Common Warts in EU-5
7.5.2 Gender specific Prevalence of Common Warts in EU-5
7.6 Japan
7.6.1 Diagnosed Prevalent cases of Common warts in Japan
7.6.2 Gender specific Prevalence of Common Warts in Japan
8 Patient Journey 1
9 Patient Journey 2
10 Emerging Therapies
10.1 Candin: Nielsen BioSciences
10.1.1 Drug Description
10.1.2 Product Development
10.1.3 Clinical Development
10.1.4 Safety and Efficacy
10.1.5 Clinical Trials Information
10.1.6 Product Profile
10.2 VBP-245: Veloce BioPharma
10.2.1 Drug Description
10.2.2 Clinical Development
10.2.3 Safety and Efficacy
10.2.4 Clinical Trials Information
10.2.5 Product Profile
10.3 VP-102: Verrica Pharmaceutical
10.3.1 Drug Description
10.3.2 Product Development
10.3.3 Clinical Development
10.3.4 Safety and Efficacy
10.3.5 Clinical Trials Information
10.3.6 Product Profile
10.4 CLS006: Maruho Co., Ltd.
10.4.1 Product Description
10.4.2 Other Developmental Activities
10.4.3 Clinical Development
10.4.4 Clinical Trials Information
10.4.5 Product Profile
10.5 A-101: Aclaris Therapeutics, Inc.
10.5.4 Product Description
10.5.2 Clinical Development
10.5.3 Clinical Trials Information
10.5.5 Product Profile
11 Current Marketed Therapies: Generics
11.1 Salicylic acid
11.2 Bleomycin
11.3 5-Fluorouracil
11.4 Cimetidine
11.5 Imiquimod
12 Other Topical Agents
12.1 Cantharidin
12.2 Retinoids
12.3 Zinc
13 Common Warts: 7 Major Market Analysis
13.1 Key Findings
13.2 Market Size of Common Warts in 7MM
13.3 Market Size of Common Warts by Therapies
14 Market Outlook
14.1 United States Market Size
14.1.1 Total Market Size of Common warts in the United States
14.1.2 Market Size of Common Warts by Therapies in United States
14.2 EU-5 Market Size
14.2.1 Total Market Size of Common warts in EU-5
14.2.2 Market Size of Common Warts by Therapies in EU-5
14.3 Japan
14.3.1 Total Market size of Common Warts in Japan
14.3.2 Market Size of Common Warts by Therapies in Japan
15 KOL Views
16 Unmet Needs
17 SWOT Analysis
18 Appendix
Companies Mentioned
- Nielsen BioSciences
- Veloce BioPharma
- Verrica Pharmaceutical
- Maruho Co., Ltd
- Aclaris Therapeutics, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/i722oz
